Charleston, SC -- (SBWIRE) -- 08/29/2013 -- Today’s Penny Stocks wants you, the investor, to have the ability to be informed in your trading decisions. Our website is designed to take you to the information you need to be at the top of your game in trading penny stocks. Today’s Penny Stocks issues news updates on the following stock: FreeSeas Inc. (NASDAQ:FREE), Galena Biopharma Inc (NASDAQ:GALE), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Curis, Inc. (NASDAQ:CRIS).
FreeSeas Inc. (NASDAQ:FREE), during the previous trading session, the stock showed a negative movement of -1.13%. FREE’s traded with volume of 1,600,129 shares, while its average trading remained 2.27 million shares. Stock’s closing price was $0.183, while it started its day-trade at $0.19. FreeSeas Inc., through its subsidiaries, provides drybulk shipping services. Its vessels carry various drybulk commodities, including iron ore, grain, and coal, as well as bauxite, phosphate, fertilizers, steel products, cement, sugar, and rice.
Has FREE Found The Bottom and Ready To Move Up? Find Out Here
Galena Biopharma Inc (NASDAQ:GALE) moving downward during the previous trading session, traded with a decline of -4.02% and closed at $2.15, after gaining total volume of 1,592,096 shares. Its opening price was $2.24. Galena Biopharma Company’s earnings per share is $-0.37, while its beta value stands at 0.65 times. Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing oncology treatments to address major unmet medical needs to advance cancer care. It is developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide.
Has GALE Found The Bottom And Ready To Gain Momentum? Find Out Here
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) reported an upsurge of 1.71%, after opening at the price of $6.60. Its closing price for the day was $6.55. BCRX’s total trading volume for the day was 1,595,945 shares, versus its average volume of 3.99 million shares. BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process.
Will BCRX Continue To Move Higher? Find Out Here
Curis, Inc. (NASDAQ:CRIS), reported to close at $4.21, with the total traded volume of 1,584,893 shares. The stock’s opening price was $4.12. The 52-week price range of the stock remained $2.66 - $4.57, while during last trade its minimum price was $4.12 and it gained its highest price of $4.30. Curis, Inc. engages in the research, development, and commercialization of cancer therapeutics. Its principal product is Erivedge capsule for treatment of adults with basal cell carcinoma (BCC) that has spread to other parts of the body or that has come back after surgery.
Why Should Investors Buy CRIS After The Recent Gain? Just Go Here and Find Out
About Today’s Penny Stocks:
Today’s Penny Stocks wants you, the investor, to have the ability to be informed in your trading decisions. Our website is designed to take you to the information you need to be at the top of your game in trading penny stocks. Today’s wants you to do your own due diligence on your investments please use our site to find the information you need on whichever investment you choose.
The disclaimer is to be read and fully understood before using our site, or joining our newsletter email list. Never invest into a stock discussed on this web site or the TodaysPennyStocks.com newsletter unless you can afford to lose your entire investment.
Please consult with a certified financial advisor before making any investment decisions.
TodaysPennyStocks.com is owned and operated by FlipVentures LLC. We are engaged in the business of advertising and promoting companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities.
Read Full Disclaimer at: http://todayspennystocks.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)